Product portfolio

At present, Biogen Canada’s focus is in the therapeutic areas of Multiple Sclerosis and Hemophilia. Biogen strives to be a pioneer in the research and development of advanced therapies for these disease areas.

Biogen Canada currently has four Multiple Sclerosis therapies on the market, and one therapy each for Hemophilia A and Hemophilia B.

Links to comprehensive information about our products are listed below, in the form of a document known as a product monograph.  This information has been approved by Health Canada and should be read and discussed in consultation with a health care professional. 

Multiple Sclerosis

AVONEX® (interferon beta-1a)

FAMPYRA® (fampridine)

PLEGRIDYTM (peginterferon beta-1a)

TECFIDERATM (dimethyl fumarate)

TYSABRI® (natalizumab)

Hemophilia

ALPROLIXTM (coagulation factor IX (recombinant), Fc fusion protein)

ELOCTATETM (antihemophilic factor (recombinant BDD), Fc fusion protein)